Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ insulin pump users can now access full compatibility with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems. The t:slim X2 insulin pump with Control-IQ technology is the #1-rated automated insulin delivery (AID) system¹, and now the first and only insulin pump in Canada that is integrated with both Dexcom G6 and Dexcom G7.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210731189/en/

t:slim X2 Insulin Pump with Dexcom G7 CGM (Photo: Business Wire)

“The commercial availability of this new offering is a testament to our decade-long partnership with Dexcom and shared commitment to continued leadership in advancing AID systems,” said Mark Novara, executive vice president and chief commercial officer of Tandem Diabetes Care. “Now, our t:slim X2 users in Canada can have access to a range of innovative tools that not only simplify diabetes management but also enhance their quality of life.”

“Through our continued partnership with Tandem, we have seen the proven benefits of automated insulin delivery. We’re proud that people living in Canada can now access the latest AID offering with Dexcom G7, our smallest and most accurate CGM²,” said André Côté, executive vice president and general manager of Dexcom Canada. “Our two organizations hold the same core value: foster technological innovation that leads to a better life for those living with diabetes. We couldn’t be more pleased to officially bring this offering to Canadians.”

In December 2023, the t:slim X2 pump with Dexcom G7 integration launched in the U.S., marking the first time an AID option was compatible with Dexcom’s latest CGM technology. Now, t:slim X2 users in Canada can experience even more choice when it comes to CGM compatibility, along with the option to spend more time in closed loop with Dexcom G7’s 30-minute sensor warm-up time, faster than any other CGM on the market.³ In addition, t:slim X2 users who pair Dexcom G7 with an Apple smartwatch⁴ can see their glucose numbers directly from their watch without having to access their pump or smartphone⁴.

Tandem will email all in-warranty t:slim X2 users in Canada with instructions on how to add the new compatibility feature free of charge via remote software update. t:slim X2 pumps pre-loaded with the updated software will begin shipping to new customers in early January 2025.

To check coverage and start the process of getting a Tandem insulin pump, please visit tandemdiabetes.ca.

To learn more about Dexcom G6 or Dexcom G7, please visit dexcom.com or ask your healthcare provider.

¹ dQ&A Canada Patient Voice H1 2024.

² Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7

³ Dexcom G7 can complete warm up within 30 minutes, whereas other CGM brands require up to an hour or longer

⁴ Smart device sold separately. To view a list of compatible devices, visit dexcom.com/compatibility. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. Dexcom G7 users must continuously have their smartphone within 10 meters (33 feet) to utilize Share/Follow.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.

Follow Tandem Diabetes Care on X @tandemdiabetes; use #tslimX2 and #TandemDiabetes.

Follow Tandem Diabetes Care on Facebook at facebook.com/TandemDiabetesCanada.

Follow Tandem Diabetes Care on LinkedIn at linkedin.com/company/tandemdiabetes.

© 2024 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ, t:slim X2, and Tandem Mobi are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. Dexcom, Dexcom G6, Dexcom G7, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. All other third-party marks are the property of their respective owners.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, the anticipated timing for the Canadian availability of the t:slim X2 pump with Dexcom G7 integration as well as our ability to provide the software update for current t:slim X2 pump users and the t:slim X2 pumps pre-loaded with Dexcom G7 integration software. These statements are subject to numerous risks and uncertainties, including our ability to start commercial scale manufacturing of the t:slim X2 pumps pre-loaded with Dexcom G7 integration software for the Canadian market, our ability to operate and maintain a system to facilitate online training for existing t:slim X2 pump customers upgrading their existing devices, and the risk that we may encounter other challenges that may delay the availability of t:slim X2 pumps pre-loaded with Dexcom G7 integration software. These and other risks are identified and described in greater detail under the “Risk Factors” heading of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors.

Responsible Use of Control-IQ Technology

Control-IQ technology does not prevent all highs and lows. Users must still bolus for meals and actively manage their diabetes. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

This product may not be right for you. Always read and follow the label.

Important Safety Information: The t:slim X2 insulin pump with Control-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Control-IQ technology, and a compatible continuous glucose monitor (CGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When used with a compatible CGM, the System can be used to automatically increase, decrease, and suspend delivery of basal insulin based on CGM sensor readings and predicted glucose values. The System can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. The pump and the System are indicated for use in individuals 6 years of age and greater. The pump and the System are intended for single user use. The pump and the System are indicated for use with NovoRapid, Admelog, Trurapi, or Humalog U-100 insulin. The System is intended for the management of Type 1 diabetes.

WARNING: Control-IQ technology should not be used by anyone under the age of 6 years old. It should also not be used in users who require less than 10 units of insulin per day or who weigh less than 25 kilograms.

The System is not indicated for use in pregnant women, people on dialysis, or critically ill users. Do not use the System if using hydroxyurea.

Users of the pump and the System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241210731189/en/